SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • November 6th, 2023 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Delaware
and existing under the laws of Delaware, having its corporate headquarters at 1 North Waukegan Road, North Chicago, Illinois 60064, on behalf of itself and its Affiliates, and AbbVie Biotechnology Ltd, a corporation organized and existing under the laws of Bermuda with a place of business at Clarendon House, 2 Church Street, Hamilton HMl 1 Bermuda (collectively and including their Affiliates, "AbbVie"); and Coherus BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having a place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, on behalf of itself and its Affiliates (including its Affiliates, "Coherus").
Coherus BioSciences, Inc. Common Stock AMENDMENT NO. 2 TO SALES AGREEMENTSales Agreement • November 6th, 2023 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
Reference is made to the Sales Agreement, dated November 8, 2022, as amended by that certain Amendment No. 1 to Sales Agreement, dated May 15, 2023 (together, the “Agreement”), by and between Coherus BioSciences, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“TD Cowen”). The Company and TD Cowen (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 15 of the Agreement, to increase the aggregate offering price under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:
